Aphria (APHA) vs. Its Competitors Head to Head Review

Share on StockTwits

Aphria (NYSE: APHA) is one of 33 publicly-traded companies in the “Medicinals & botanicals” industry, but how does it weigh in compared to its competitors? We will compare Aphria to similar businesses based on the strength of its dividends, profitability, risk, institutional ownership, analyst recommendations, valuation and earnings.

Profitability

This table compares Aphria and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aphria 5.75% -0.30% -0.21%
Aphria Competitors -1,150.45% -258.05% -48.97%

Earnings and Valuation

This table compares Aphria and its competitors gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Aphria $179.29 million -$12.48 million -40.27
Aphria Competitors $219.25 million -$99.48 million 2.15

Aphria’s competitors have higher revenue, but lower earnings than Aphria. Aphria is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

Aphria has a beta of 2.19, indicating that its share price is 119% more volatile than the S&P 500. Comparatively, Aphria’s competitors have a beta of 2.57, indicating that their average share price is 157% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Aphria and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aphria 0 0 8 0 3.00
Aphria Competitors 135 357 403 14 2.33

Aphria currently has a consensus price target of $8.83, indicating a potential upside of 99.29%. As a group, “Medicinals & botanicals” companies have a potential upside of 117.84%. Given Aphria’s competitors higher probable upside, analysts plainly believe Aphria has less favorable growth aspects than its competitors.

Institutional & Insider Ownership

9.6% of Aphria shares are held by institutional investors. Comparatively, 21.6% of shares of all “Medicinals & botanicals” companies are held by institutional investors. 25.8% of shares of all “Medicinals & botanicals” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Aphria beats its competitors on 7 of the 13 factors compared.

About Aphria

Aphria Inc. produces and sells medical cannabis in Canada and internationally. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It serves patients and health professionals. The company also sells its products online. Aphria Inc. is headquartered in Leamington, Canada.

Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Aphria  vs. Its Competitors Head to Head Review
Aphria vs. Its Competitors Head to Head Review
Nektar Therapeutics  Director Jeffrey Robert Ajer Sells 3,250 Shares of Stock
Nektar Therapeutics Director Jeffrey Robert Ajer Sells 3,250 Shares of Stock
Two Sigma Advisers LP Increases Stake in RLI Corp
Two Sigma Advisers LP Increases Stake in RLI Corp
Cupid  Posts Quarterly  Earnings Results
Cupid Posts Quarterly Earnings Results
Cupid  Announces Quarterly  Earnings Results
Cupid Announces Quarterly Earnings Results
Philip Bowman Purchases 50,000 Shares of Kathmandu Holdings Ltd  Stock
Philip Bowman Purchases 50,000 Shares of Kathmandu Holdings Ltd Stock


 
© 2006-2020 Zolmax.